CTOs on the Move

Benchmark Scientific

www.benchmarkscientific.com

 
Benchmark Scientific is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Metropolitan Chicago Healthcare Council

Metropolitan Chicago Healthcare Council is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Burke Rehabilitation Hospital

The Burke Rehabilitation Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. The Burke Rehabilitation Hospital is based in White Plains, NY. You can find more information on The Burke Rehabilitation Hospital at www.burke.org

Governor'S Glen Memory Imprd

Governor'S Glen Memory Imprd is a Forest Park, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arthrex

Arthrex, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Arthrex, Inc. is based in Naples, FL. You can find more information on Arthrex, Inc. at www.arthrex.com

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.